✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Janoshik
Batch TIRZ-CA-26A-01
Dual GLP-1 / GIP Research Peptide
Tirzepatide is a dual-agonist research peptide studied for its interaction with incretin-related signaling pathways involved in metabolic regulation. Laboratory investigations often focus on its receptor activity, downstream effects on glucose-handling systems, and broader energy-balance mechanisms in controlled experimental models.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
In scientific literature, tirzepatide is studied in models examining receptor-mediated signaling cascades, metabolic pathway interaction, and downstream cellular response systems under in vitro and preclinical research conditions.
Third-party tested for purity, ID, quantity.
Tirzepatide is a synthetic dual receptor peptide evaluated in research focused on GLP-1 and GIP receptor activity. It has been examined in experimental models investigating receptor-binding dynamics, incretin-related signaling pathways, and endocrine regulatory systems.
Preclinical and clinical research publications have explored its receptor interaction profile and downstream signaling activity within controlled study frameworks.
Tirzepatide was developed as part of research efforts exploring dual incretin receptor agonism. Investigations into GLP-1 and GIP pathway modulation led to the synthesis of compounds designed to engage both receptor systems simultaneously.
Subsequent research publications documented its receptor-binding properties and multi-pathway signaling activity within experimental environments.
Laboratory investigations into tirzepatide have examined its dual incretin receptor activity and signaling behavior across GLP-1 and GIP pathways. Research models evaluate receptor activation dynamics, incretin-related signaling cascades, and metabolic regulatory frameworks under controlled in vitro and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 30mg of lyophilized tirzepatide. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the lyophilized peptide. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).
PubMedTirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).
PubMedTirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811–1824.
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$180.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$70.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$95.00
Synthetic thymosin beta analog studied for cellular migration, actin regulation, and repair signaling pathways
From$60.00
